Clinical Trial Update: Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety, tolerability, and efficacy of topical PF-06763809 in mild to moderate chronic plaque psoriasis; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• PF-06763809 (PF-06763809)

Snippet

Sponsor: Pfizer | Conditions: Psoriasis | Phase 1 | Status: COMPLETED | Results posted: 2020-06-25